Screener
Bicara Therapeutics BCAX Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $1.44M.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
FAQ
- What is Bicara Therapeutics's total debt?
- Bicara Therapeutics (BCAX) reported total debt of $1.44M in Q1 2026.
- How has Bicara Therapeutics's total debt changed year-over-year?
- Bicara Therapeutics's total debt increased by 143.8% year-over-year, from $591K to $1.44M.
- What is the long-term trend for Bicara Therapeutics's total debt?
- Over 2 years (2023 to 2025), Bicara Therapeutics's total debt has grown at a 61.3% compound annual growth rate (CAGR), from $657K to $1.71M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about Bicara Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude